Bone Marrow Transplantation for Treatment of the Col1a2+/G610C Osteogenesis Imperfecta Mouse Model
- 129 Downloads
Bone marrow transplantation (BMT) of healthy donor cells has been postulated as a strategy for treating osteogenesis imperfecta (OI) and other bone fragility disorders. The effect of engraftment by tail vein injection and/or marrow ablation by 6 Gy whole body irradiation were tested in Col1a2+/G610C (OI) mice as a model of mild-moderate OI. Dual-emission X-ray absorptiometry, microCT, and 4-point bending were used to measure bone volume (BV), bone mineral density (BMD), and biomechanical strength. BV, BMD, and mechanical strength were reduced in OI mice compared to wild type (WT) controls. BMT with and without irradiation yielded no difference in BV and BMD outcomes for both OI and WT mice, at 3 weeks. Transplantation of OI cells into OI mice to test for paracrine effects of BMT also showed no difference with non-transplanted OI mice. In a parallel cell tracking study, donor marrow was taken from transgenic mice constitutively expressing tdTomato and transplanted into WT mice. Lineage tracking demonstrated that irradiation considerably enhanced engraftment of tdTomato+ cells. However, tdTomato+ cells predominantly expressed TRAP and not AP, indicating engrafted donor cells were chiefly from the hematopoietic lineages. These data show that whole marrow transplantation fails to rescue the bone phenotype of Col1a2+/G610C (OI) mice and that osteopoietic engraftment is not significantly enhanced by irradiation. These findings are highly relevant to modern approaches focused on the gene repair of patient cells ex vivo and their subsequent reintroduction into the osteopoietic compartment via the circulation.
KeywordsOsteogenesis imperfecta Bone marrow transplantation Lineage tracking Osteoblasts Osteoclasts
LRL performed the bulk of the experimental research and analysis. LP performed animal injection and animal care. SG carried out total body irradiation. LCC advised on microscopy and captured confocal images, TLC carried out biomechanical testing. DGL, CM, and AS conceived the study and designed the experimental plan. LRL and AS drafted the manuscript, with all authors providing critical feedback.
This work was supported by philanthropic funding from the Sticks and Stones Foundation.
Compliance with Ethical Standards
Conflict of interest
Aaron Schindeler has received funding support from Amgen, Novartis AG, Celgene Corp, and N8 Medical for research unrelated to this study. Craig F. Munns has received research support from Alexion, Novartis AG and is a consultant for Alexion and Novartis AG for research unrelated to this project. Tegan L. Cheng and David G. Little received philanthropic funding from Hyundai Help for Kids, which is unrelated to this work.
Human and Animal Rights and Informed Consent
Animal experiments were approved by The Children’s Hospital at Westmead/Children’s Medical Research Institute Animal Ethics Committee under protocol K315. Informed Consent was not required as no human was involved.
- 6.Horwitz EM, Gordon PL, Koo WK, Marx JC, Neel MD, McNall RY, Muul L, Hofmann T (2002) Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: implications for cell therapy of bone. Proc Natl Acad Sci USA 99(13):8932–8937CrossRefPubMedGoogle Scholar
- 9.Ricci P, Tauchmanova L, Risitano AM, Carella C, Mazziotti G, Lombardi G, Colao A, Rotoli B, Selleri C (2006) Imbalance of the osteoprotegerin/RANKL ratio in bone marrow microenvironment after allogeneic hemopoietic stem cell transplantation. Transplantation 82(11):1449–1456CrossRefPubMedGoogle Scholar
- 10.Otsuru S, Desbourdes L, Guess AJ, Hofmann TJ, Relation T, Kaito T, Dominici M, Iwamoto M, Horwitz EM (2017) Extracellular vesicles released from mesenchymal stromal cells stimulate bone growth in osteogenesis imperfecta. Cytotherapy 20(1):62–73Google Scholar
- 12.Masci M, Wang M, Imbert L, Barnes AM, Spevak L, Lukashova L, Huang Y, Ma Y, Marini JC, Jacobsen CM, Warman ML, Boskey AL (2016) Bone mineral properties in growing Col1a2+/G610C mice, an animal model of osteogenesis imperfecta. Bone 87:120–129. https://doi.org/10.1016/j.bone.2016.04.011 CrossRefPubMedPubMedCentralGoogle Scholar
- 18.Pereira RF, O’Hara MD, Laptev AV, Halford KW, Pollard MD, Class R, Simon D, Livezey K, Prockop DJ (1998) Marrow stromal cells as a source of progenitor cells for nonhematopoietic tissues in transgenic mice with a phenotype of osteogenesis imperfecta. Proc Natl Acad Sci USA 95(3):1142–1147CrossRefPubMedPubMedCentralGoogle Scholar
- 19.Guillot PV, Abass O, Bassett JD, Shefelbine SJ, Bou-Gharios G, Chan J, Kurata H, Williams GR, Polak J, Fisk NM (2008) Intrauterine transplantation of human fetal mesenchymal stem cells from first-trimester blood repairs bone and reduces fractures in osteogenesis imperfecta mice. Blood 111(3):1717–1725CrossRefPubMedPubMedCentralGoogle Scholar
- 21.Otsuru S, Gordon PL, Shimono K, Jethva R, Marino R, Phillips CL, Hofmann TJ, Veronesi E, Dominici M, Iwamoto M (2012) Transplanted bone marrow mononuclear cells and MSCs impart clinical benefit to children with osteogenesis imperfecta through different mechanisms. Blood 120(9):1933–1941CrossRefPubMedPubMedCentralGoogle Scholar